Cytokine TRAIL selectively induces apoptosis in vitro and in vivo in tumor cells without affecting normal cells, but its therapeutic application is limited, since many primary tumors are insensitive to TRAIL. To improve the efficiency of TRAIL, we have previously developed TRAIL mutant variant DR5-B, which binds the apoptosis-inducing death receptor DR5 as efficiently as wild type TRAIL, but shows almost no affinity to other receptors. In this study, we investigated the effect of the chemotherapeutic agent cisplatin on the cytotoxicity of TRAIL variants in 12 tumor cell lines of various origin. Cisplatin effectively enhances the cytotoxic activity of TRAIL preparations. The synergistic effect is most pronounced in the prostate cancer cell lines, where the combined effect exceeds the sum of the separate effects by more than 2 times. The cytotoxicity of DR5-B variant is significantly higher compared to wild-type TRAIL in combination with cisplatin in 9 of 12 tumor cell lines.
Doklady. Biochemistry and biophysics. 2018 Jan 03 [Epub]
M E Gasparian, M L Bychkov, A V Yagolovich, M P Kirpichnikov, D A Dolgikh
Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997, Russia. ., Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997, Russia.